Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier"
- PMID: 1563006
Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier"
Abstract
Monoclonal antibodies and other biological ligands tend to distribute nonuniformly in bulky tumors after systemic administration. In part, that observation reflects intrinsic heterogeneity of the tumor; in part, it represents poor percolation through tumor substance. Theoretical considerations led us several years ago to formulate the "binding site barrier" hypothesis, the idea that macromolecular ligands could be prevented from penetrating tumors by the very fact of their successful binding to the target receptor. All else being equal, the higher the density of target moieties (e.g., antigens) and the higher the affinity, the greater the barrier. Experimental evidence for this hypothesis remained circumstantial until we recently obtained direct experimental verification in an animal tumor system. As shown by calculations in the present study, metabolism of ligand in free form or once it has bound to the target can also limit dramatically the extent of penetration. The PERC program package, developed to examine these issues in the case of monoclonal antibodies, has now been applied to other types of ligands as well. We speculate that the same microscopic factors have influenced the evolution of biological ligands, such as the autocrine-paracrine and chemotactic factors. Micropharmacological issues (binding sites, molecular size, and charge) should be taken into account as we design the next generation of biological ligands for systemic administration. The same issues are, perhaps, even more important with respect to molecular design of biological factors to be secreted by genetically modified cells in the treatment of cancer and in cancer vaccines. Since the PERC calculations and experiments relate to aggregates of tumor cells no more than a few hundred micron across, the ideas appear relevant to the problems of early detection and intervention. However, barriers associated with organized epithelial cell layers and basement membrane in the case of early carcinomas and carcinomatous change remain to be understood.
Similar articles
-
Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier.Cancer Res. 1992 Oct 1;52(19):5144-53. Cancer Res. 1992. PMID: 1327501
-
An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier".Cancer Res. 1991 Sep 15;51(18):4776-84. Cancer Res. 1991. PMID: 1893370
-
Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors.Cancer Res. 1989 Oct 15;49(20):5656-63. Cancer Res. 1989. PMID: 2790783
-
Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.Handb Exp Pharmacol. 2008;(181):291-328. doi: 10.1007/978-3-540-73259-4_13. Handb Exp Pharmacol. 2008. PMID: 18071951 Review.
-
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.Cancer Res. 1990 Feb 1;50(3 Suppl):814s-819s. Cancer Res. 1990. PMID: 2404582 Review.
Cited by
-
Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):683-710. doi: 10.1007/s10928-012-9279-8. Epub 2012 Nov 27. J Pharmacokinet Pharmacodyn. 2012. PMID: 23184417 Free PMC article.
-
The Therapeutic Potential of Nanobodies.BioDrugs. 2020 Feb;34(1):11-26. doi: 10.1007/s40259-019-00392-z. BioDrugs. 2020. PMID: 31686399 Free PMC article. Review.
-
Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers.Clin Cancer Res. 2020 Jun 1;26(11):2582-2594. doi: 10.1158/1078-0432.CCR-19-3717. Epub 2020 Jan 24. Clin Cancer Res. 2020. PMID: 31980465 Free PMC article.
-
Aptamer-conjugated polymeric nanoparticles for targeted cancer therapy.Drug Deliv Transl Res. 2012 Dec;2(6):418-36. doi: 10.1007/s13346-012-0104-0. Drug Deliv Transl Res. 2012. PMID: 25787323
-
Strategies for advancing cancer nanomedicine.Nat Mater. 2013 Nov;12(11):958-62. doi: 10.1038/nmat3792. Nat Mater. 2013. PMID: 24150413 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials